Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage

ConditionsPostpartum Hemorrhage Delivery Complication Cesarean Section Complications Perinatal Problems

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexFemale

AgeNot listed

SponsorMahidol University

About this trial

Postpartum hemorrhage (PPH) is the global leading cause of maternal death, with 20-30% of maternal deaths in Thailand linked to hemorrhage. The WOMAN Trial (2017) provided strong evidence that administering tranexamic acid (TXA)within three hours of bleeding onset lowered PPH-related mortality by 31%. Consequently, the World Health Organization (WHO) updated its guidelines, recommending TXA as part of the standard treatment package for all PPH cases. Following this, the use of TXA has been widely adopted globally and increased in Thailand. A recent study at a major Thai university hospital observed a significant increase in TXA administration after 2017. The current study aims to further analyze the recent growth rate of TXA use and its impact on obstetric and perinatal outcomes during cesarean deliveries with PPH.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

1. Patients underwent cesarean delivery with primary postpartum hemorrhage

Disqualifiers

Gestational age at less than 24 weeks

Absence of the anesthetic record

Received tranexamic acid in the antepartum period

Blood loss less than 1,000 ml

Trial population

Patients underwent cesarean delivery with diagnosis of primary postpartum hemorrhage at Siriraj Hospital, Bangkok, Thailand

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

Tranexamic acid
Drug
The number of patients received tranexamic acid after postpartum hemorrhage

Treatment groups

648 Participants

are divided into 2 treatment groups

Group A: Tranexamic acid group1 intervention

Group B: Non tranexamic acid group0 interventions

Trial outcomes